When it comes to establishing the right treatment at the right time for cancer, in vitro diagnostics play a significant role by detecting early warning signs and individual risk factors. They also support with prevention and early intervention and provide knowledge that informs targeted treatment pathways and decision making.
We focus on blood cancers such as myeloma and lymphoma, as well as colorectal and prostate cancers. The variable prognosis for patients with B-cell malignancies in particular, offers huge opportunities for personalised treatment.
There is an urgent need for new biomarkers to predict response to new immunotherapy treatments, reduce waiting times and allow more accurate diagnosis. We are working with commercial partners to evaluate new predictive biomarkers for colorectal and prostate cancers.